Detail akcie MediWound online

Business Summary: Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Mediwound Ltd revenues increased 5% to $15.1M. Net loss decreased 37% to $16.7M. Revenues reflect Total Revenues increase of 62% to $15.1M. Lower net loss reflects Financial income increase from $11.2M (expense) to $866K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.71 to -$1.54.